AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient Français
Following a national competition, AbbVie and SpinUp – the University of Toronto's lab-based, life sciences accelerator – announce Neuropeutics Inc as recipient of first AbbVie Biotech Innovators Award
Neuropeutics Inc receives a year of laboratory space and equipment at no cost, as well as access to support and mentorship
TORONTO, May 22, 2025 /CNW/ - AbbVie (NYSE: ABBV) in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the recipient of the AbbVie Biotech Innovators Award, a national prize to help foster innovation and support growth in Canada's life sciences sector. Following a competitive selection process, the award, funded by AbbVie, has been granted to Neuropeutics Inc for developing small molecules preventing and reversing protein aggregation as therapeutics for neurodegenerative diseases.
"We are delighted to have this opportunity to collaborate with a global biopharmaceutical company such as AbbVie, and the University of Toronto's SpinUp, to advance Neuropeutics' therapeutic research and development across multiple neurodegenerative diseases. At Neuropeutics, we are committed to developing targeted therapies to extend neurodegenerative disease patients' survival and improve their quality of life. This award allows us to pursue that mission with greater momentum," said Dr. Marc Shenouda, CEO & Co-Founder of Neuropeutics Inc.
Neuropeutics Inc's scientific entrepreneurial spirit directly aligns with the mandate of the AbbVie Biotech Innovators Award to foster research, innovation and growth within Canada's life sciences sector. A hallmark of neurodegenerative diseases is protein aggregation. One such protein is TDP-43, a normally nuclear DNA/RNA binding protein, which in disease conditions becomes mislocalized and forms cytoplasmic aggregates causing neuronal toxicity. Neuropeutics Inc has developed a novel strategy to address diseases such as: Amyotrophic Lateral Sclerosis (ALS), Frontotemporal dementia, Alzheimer's disease, Huntington's disease and Parkinson's disease.
"It was impressive and motivating to see the variety of entries and the calibre of early-stage biotech companies who applied for the Award. We thank all who participated in this life science competition," said Rami Fayed, Vice President and General Manager of AbbVie Canada. "After a rigorous evaluation process, it is with great pleasure that we are announcing that Neuropeutics has been named the recipient of the AbbVie Biotech Innovators Award for its pioneering work in neurodegenerative diseases. We look forward to supporting the journey of Neuropeutics, in collaboration with SpinUp, to accelerate their efforts to deliver life-changing innovation to patients."
"Congratulations to Neuropeutics on being the first AbbVie Biotech Innovators Award recipient, and welcome to SpinUp – the University of Toronto's wet lab incubator," said France Gagnon, Vice-Principal, Research and Innovation at the University of Toronto Mississauga. "This is the place where the potential of Neuropeutics' work in neurodegenerative diseases can be realized and the impact on life sciences can be game changing. We are pleased to collaborate with AbbVie, a global leader in the biopharmaceutical industry, to offer this unique opportunity to this competitively chosen startup."
The AbbVie Biotech Innovators Award was launched in 2024 in collaboration with SpinUp, a purpose-built laboratory for chemistry and biological work – or wet lab – incubator at the University of Toronto. The Award is to support early-stage Canadian biotechnology startup companies with the potential to generate transformational therapies in areas that align with AbbVie's therapeutic areas of focus: immunology, oncology, neuroscience, and eye care. Neuropeutics Inc will receive a year of laboratory space at no cost, in addition to access to SpinUp's core equipment, services, entrepreneurship programming, and research talent community at the University of Toronto. Neuropeutics Inc will also benefit from mentorship by AbbVie's scientific and business executives.
For more information on the AbbVie Biotech Innovators Award, please visit: https://spinup.utm.utoronto.ca/biotech-innovators-award/.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
For more information about AbbVie, please visit us at www.abbvie.ca. Follow AbbVie Canada on Instagram or find us on LinkedIn.
About SpinUp
SpinUp is the first wet lab startup incubator at the University of Toronto, Canada's leading centre for learning and discovery and one of the world's top-two universities for health science productivity. SpinUp is purpose built to drive life science innovation. It offers early-stage start-ups access to outstanding and highly subsidized wet lab space, equipment, entrepreneurship programming and expertise at a brand new, state-of-the-art research facility at U of T's Mississauga campus. Visit our website at spinup.utm.utoronto.ca and connect with us on Instagram and LinkedIn.
SpinUp is proudly part of U of T Entrepreneurship, a network of 12 accelerators across three campuses. Over the past 10 years, this network has supported more than 1,200 capital-backed companies, which have created 17,000 jobs and raised $12 billion in external investment. U of T now launches more research-based start-ups than any university in North America outside of MIT. The AbbVie Biotech Innovators Award is part of U of T Mississauga's Blue Ticket program at SpinUp, which provides a one-year SpinUp membership.
About Neuropeutics Inc
Neuropeutics is a for-profit Canadian pharmaceutical company developing targeted therapies to extend neurodegenerative disease patients' survival and improve their quality of life. To learn more, please visit us at www.neuropeutics.ca, contact us at [email protected], and connect with us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil
New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national research excellence LONDON, June 2, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the renewal of its multi-year partnership with CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), significantly expanding access to trusted Academia & Government and Life Sciences & Healthcare data across over 400 Brazilian institutions. As compared to the previous contract, the agreement increases institutional coverage by 57%, extending the reach of high-quality research tools to universities and research centers across Brazil — from major metropolitan areas to the country's most remote regions. As a key agency under Brazil's Ministry of Education, CAPES plays a vital role in advancing postgraduate education, supporting high-level training, and fostering international scientific collaboration. A long-standing partner to CAPES, Clarivate began its collaboration with the agency in 2001, when the Web of Science became one of the first databases integrated into the CAPES Portal. This new agreement builds on that legacy, delivering enhanced access to solutions including Web of Science, Journal Citation Reports, Cortellis Drug Discovery Intelligence and Derwent Innovation Index. By bringing together world-class data and insights from academic research and the life sciences and healthcare sectors, the agreement empowers researchers and practitioners at all levels — including scholars, policy advisors, biomedical scientists and healthcare professionals — to conduct innovative research, develop new treatments, improve patient care, and inform policy decisions. It provides broad access to critical information, advancing evidence-based discovery, education and decision-making across disciplines. Matti Shem Tov, Chief Executive Officer, Clarivate, said:"This expanded partnership with CAPES is a powerful example of how strategic collaboration can accelerate research and innovation on a national scale. Brazil has made remarkable progress in advancing scientific excellence and global collaboration. We're proud to support this momentum by providing trusted data, insights, and technology to researchers across the country — from early discovery through impact assessment. Our shared commitment to expanding access and fostering innovation will continue to shape the future of research in Brazil and beyond." Denise Pires de Carvalho, President, CAPES, said: "Brazil is experiencing a moment of growing scientific output beyond its major urban centers, with resources now being distributed in a more equitable and democratic way to boost productivity across all regions. This collaboration with Clarivate enables us to better understand the scientific production profile of Brazilian institutions and supports more informed investment decisions to reduce regional disparities, which remains a significant national challenge. Many researchers in the North, Northeast and Center-West have limited access to the resources needed to give visibility to their work and expanding that access can make a meaningful difference." The renewed partnership reflects a shared commitment to democratizing access to critical scientific information and enabling data-driven research excellence. Through Web of Science, Journal Citation Reports, and Derwent Innovation Index, academic institutions and government agencies gain deeper visibility into global research trends, publication impact, and innovation pathways — supporting policy development, institutional benchmarking, and scholarly advancement. Complementing these capabilities, expanded access to Cortellis Drug Discovery Intelligence equips Brazil's life sciences community — including postgraduate students, faculty, and biomedical researchers — with comprehensive insights across biology, pharmacology, and chemistry. From disease understanding and drug interactions to clinical studies and intellectual property, users can more efficiently navigate the full R&D lifecycle and accelerate decision-making in high-impact research areas. By significantly expanding access to trusted research and innovation tools, this agreement supports CAPES' mission to reduce regional disparities and foster inclusive academic excellence. Institutions from across Brazil — from leading urban universities to those in underserved and remote regions — can now leverage high-quality data to strengthen postgraduate programs, accelerate innovation, and elevate the global visibility of Brazilian research. Clarivate values its collaboration with CAPES on this initiative to help shape a more connected, informed and future-ready research ecosystem across Brazil, and stands as a resource for academic consortia worldwide seeking to expand access to trusted research, data and insights. To learn more about this partnership and the solutions now available to CAPES institutions, visit here. Notes to editors According to the most recent Institute for Scientific Information G20 research and innovation scorecard: Around 40% of Brazilian research output is internationally collaborative, with many strong bilateral partnerships with the United States. It also participates in larger collaborations involving the U.S., the U.K., Spain, Germany, and France. Compared with other internationally collaborative output, these partnerships are producing papers with above average impact. Its research output shows a strong focus on Sustainable Development Goals (SDGs) Zero Hunger (SDG 2) and Life on Land (SDG 15), with impact for both around 0.7 to 0.8 times the world average. More broadly, Brazilian research output has a strong focus on the Life Sciences, while its output in Medicine has impact around 1.1 times the world average. Around 40% of output is published in open access (OA) journals, with their Humanities and Languages output 2.4 times more likely to be published in an OA journal than the G20 average. About Clarivate Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit About Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) is a consortium dedicated to expanding and strengthening postgraduate studies in Brazil. It ensures the quality of academic programs while fostering the development of highly qualified professionals in research, teaching, and other strategic scientific fields. Media contacts: Clarivate Catherine Daniel Director, External Communications – Life Sciences & Healthcare [email protected] CAPES João Mendes Communications [email protected] SOURCE Clarivate Plc
Toronto Star
15 hours ago
- Toronto Star
Gardiner, Don Valley Parkway to be shut down on Sunday for a bike ride. What you need to know
If you are planning on being in Toronto today, you may want to plan alternative routes as the downtown core, Don Valley Parkway and Gardiner Expressway will see disruptions. The DVP from the Gardiner Expressway to York Mills Road and the Gardiner from the South Kingsway to the DVP will be closed for the Bike for Brain Health. Participants will take over Toronto's highways from 2 a.m. until 4 p.m., riding traffic free, while raising awareness and donations for Alzheimer's research. ARTICLE CONTINUES BELOW Gta 'An opportunity to say thank you': UHN's first large-scale fundraising walk celebrates health care and innovation We Walk UHNited's Saturday event advocates for Canadian health care and celebrated the patients helped by the hospital network. Gta 'An opportunity to say thank you': UHN's first large-scale fundraising walk celebrates health care and innovation We Walk UHNited's Saturday event advocates for Canadian health care and celebrated the patients helped by the hospital network. Roads surrounding the Exhibition Place such as Saskatchewan Road, British Columbia Road, Princes Boulevard, Quebec Street, PEI Crescent and Dufferin Street between Springhurst Avenue and Saskatchewan Road will also be closed. While public transportation is recommended, the event has disrupted the 329 Dufferin night buses Sunday morning. The route will not enter the Canadian National Exhibition grounds and will stop at the Dufferin Gate Loop. The TTC warned riders that the event may also cause delays to the 91 Woodbine and 95 York Mills routes until 4 p.m. Adding to the weekend's disruptions, the first-ever We Walk UHNited fundraiser took place on Saturday, with 2K and 5K walks in support of the UHN Foundation leading to multiple downtown street closures through the morning and early afternoon. With files from Kristjan Lautens
Globe and Mail
a day ago
- Globe and Mail
These 3 Dow Stocks Are Set to Soar in 2025 and Beyond
These are tricky times for investors. Oh, the market's never exactly easy to navigate. Things are proving particularly unpredictable right now, however. Some tickers are performing well when they seemingly shouldn't be, while others are lagging when they should be soaring. Never even mind all the uncertainty stemming from the ongoing tariff wars. If you can take a step back and look through all the near-term fuzziness at the bigger picture though, many of the market's long-term winners become clear. Three of its best bets right now, in fact, are blue chip stocks that help make up the Dow Jones Industrial Average. Here's a closer look at each one and why they're all likely to soar this year ... and beyond. 1. Home Depot At first blush, Home Depot (NYSE: HD) seems like a name to avoid right now. Consumers are feeling fiscally pinched, and mortgage loan rates are holding near multi-year highs. Both work against a home improvement retailer that relies on professional contractors for half of its revenue (which, of course, means the other half comes from consumers themselves). Be wary of jumping to conclusions based on a mere perception of data, however. Things may not be quite as dire as they appear at this time. Take, for instance, last month's sales of newly built homes. Despite the challenging economic environment, the U.S. Census Bureau reports April's new home sales reached a multi-year high annualized pace of 743,000 units. Meanwhile, the Conference Board's consumer-confidence measure for May bounced back quite a bit from April's plunge, with expectations that international trade deals will turn constructive again soon enough. Harvard University's Leading Indicator of Remodeling Activity (LIRA) index indicates that remodeling and home-upgrade outlays are likely to grow 2.5% through the first quarter of the coming year. That's not exactly thrilling, but it is a nice turnaround from last year's 1.5% dip. This stock's weakness since the beginning of the year doesn't reflect any of this upside. Just don't tarry if you want to capitalize on the mostly unmerited pullback. Even if you're not looking for dividend income right now, you'll be plugging in while this ticker's forward-looking dividend yield stands at a healthy 2.5%. That's not a bad little add-on perk for owning a stock that could -- and likely will -- start soaring at the first real hint of an economic rebound. It's just going to take a little patience. 2. Walt Disney Speaking of patience, there's a light at the end of the tunnel for Walt Disney (NYSE: DIS) shareholders who've stuck with the entertainment stock through three long years of underperformance. What's changed? Almost everything, really. Take its streaming business as an example. After years of complicated and sometimes conflicted partial ownership of Hulu and the reporting of its specific results, the company is offloading this particular streaming service onto FuboTV so it can focus on its flagship platform Disney+. It's also still on schedule to debut a stand-alone streaming version of ESPN later this year, pitting it directly against its cable television partners that offer the very same programming. Although this could accelerate the cord-cutting movement that's already hurting Disney's other cable TV channels like The Disney Channel, National Geographic, Freeform, and broadcast network ABC, on balance, the company is better served by offering this sports-focused streaming service that consumers increasingly want. And this is all taking shape at a time when Disney's collective non-sports streaming services (likely led by Disney+) are starting to show a consistent operating income anyway. Connect the dots. The initial vision of sustainable streaming dominance is finally coming to fruition. In the meantime, higher theme park ticket prices don't appear to be deterring crowds even a little bit -- its parks are still as packed as they've ever been. During March, in fact, heavy spring break foot traffic meant its theme parks were forced to deny entry to many walk-up, would-be guests. To this end, last quarter's parks and experiences revenue improved another 9% year over year, driving a 13% uptick in operating income. It's encouraging simply because parks and experiences account for nearly 40% of Disney's total revenue and are its biggest profit producer, consistently accounting for more than half of its bottom line. There's still plenty to figure out to be sure, like its film business, which has lost its magic of late. But there's hope on this front as well. CEO Bob Iger commented in early May that the releases scheduled for the next 18 months are some of the best work Disney's movie studio has done since 2019. Bottom line? This is the regrouped Walt Disney Company the world's been waiting on. Now the stock just needs the right nudge. 3. Walmart Finally, add Walmart (NYSE: WMT) to your list of Dow stocks that could start climbing this year and continue climbing indefinitely. You know the company. Walmart is, of course, the world's biggest brick-and-mortar retailer, doing $681 billion worth of business last year, and turning $29.7 billion of that into operating income and about $20 billion in net income. Revenue improved 5.6% year over year, while profits jumped nearly 10% (and per-share profits grew a little more than 13% year over year). Both are extensions of well-established trends that should carry on at the same basic pace for at least the next few years. This alone isn't the reason you'll want to have a stake in Walmart while shares are still stuck in a bit of a rut since peaking in February, though. It's not easy to see unless you're looking for it. But the consumer/retailing landscape is changing. Value means more than brand again, and shoppers don't really care where or how they find value. That's why Walmart repeatedly reported market share growth among households earning in excess of $100,000 in 2023 and 2024 ... when inflation was relentless. The retailer's ongoing evolution isn't solely about value. It's delivering the convenience consumers are increasingly seeking by offering actual delivery. Last quarter's membership income (mostly from Walmart+ memberships) was up nearly 15% year over year. Although the company itself doesn't regularly report the number, it's easily in the tens of millions now and clearly still growing. Walmart also continues to blur the lines separating retailing, media, and advertising. Last year's worldwide advertising revenue reached $4.4 billion, up 27% year over year. While the bulk of that came from brands promoting their goods at the company's acquisition of connected-television brand Vizio, completed in December, opens the door to a new opportunity to connect itself and its vendors with nearly 20 million TV watchers. Simply put, this isn't the Walmart of yesteryear. This is a retailer that's quietly become a powerful omnichannel outfit that does digital about as well as any rival. The fact that it's bigger than any other brick-and-mortar retailer just means it enjoys an unfair advantage whenever it pulls one of the aforementioned growth levers. The market should start seeing -- and appreciating -- this not-so-subtle nuance sooner rather than later. Should you invest $1,000 in Home Depot right now? Before you buy stock in Home Depot, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Home Depot wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor 's total average return is979% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
